Funded Biotechnology Startups in Italy
The 24 biotechnology companies listed here span rounds closed between May 2020 and September 2025, with a measurable cluster of activity in 2022 and a seco…
The 24 biotechnology companies listed here span rounds closed between May 2020 and September 2025, with a measurable cluster of activity in 2022 and a second wave from late 2024 onward. Northern Italy dominates the geographic distribution: Lombardia leads with five companies — Genenta Science ($22M, Milano, March 2025), PHSE ($17M, Lodi, October 2024), MOGU ($12M Series A, Varese, January 2024), GFBiochemicals ($16M Series A, Milan, May 2022), and VoiceMe (Milan, undisclosed). Piemonte and Emilia-Romagna each contribute four companies, including Torino-based Kither Biotech's $20M Series B in March 2022, the only round of that stage in the dataset.
Round structures vary considerably. Series Unknown designations are the most frequent label across seven companies, while five raised at Seed stage — ranging from FTnet's $5M in Napoli to Oraigo's $1M in Padova, both in mid-2025. Debt financing appears three times, including IRBM's $16M raise in Pomezia (April 2022) and React4life's $900K in Genoa (March 2022). Three rounds list undisclosed amounts.
Most recent rounds
24 shownRelated listings
Frequently asked
What are the largest disclosed rounds among these Italian biotech companies?
Sibylla Biotech (Trento) raised $23M in a Series A in October 2022, followed by Genenta Science (Milano) at $22M in March 2025 and Kither Biotech (Torino) at $20M in a Series B in March 2022. PHSE (Lodi) and GFBiochemicals (Milan) each raised $16M — one classified as Series Unknown, one as Series A.
Which Italian regions have the most biotech funding activity in this dataset?
Lombardia leads with five companies: Genenta Science and GFBiochemicals in Milano, PHSE in Lodi, MOGU in Varese, and VoiceMe in Milan. Piemonte (Kither Biotech, Resalis Therapeutics, NOUS Energy, Composite Research) and Emilia-Romagna (CellPly, Stem Sel Srl, Neuron Guard, PinCell) each account for four companies.
What funding stages appear most often in Italian biotech here?
Series Unknown is the most common label, covering seven companies including Genenta Science and PHSE. Seed rounds appear five times, and Series A four times — Sibylla Biotech, GFBiochemicals, MOGU, and Sensosan. Kither Biotech's $20M raise is the only Series B in the 24 rows shown.
How active has Italian biotech funding been in 2024 and 2025?
Ten of the 24 companies closed rounds in 2024 or 2025. The most recent is Yeastime (Rome), a $1M venture round in September 2025. Genenta Science's $22M raise in March 2025 and PHSE's $17M in October 2024 represent the largest among that cohort.
How common are undisclosed round sizes in this segment?
Three of the 24 rounds — Resalis Therapeutics (Torino), Diatech Pharmacogenetics (Jesi), and VoiceMe (Milan) — list amounts as undisclosed. The remaining 21 entries report a specific figure, making amount visibility relatively high for this segment.
Do seed-stage Italian biotech startups raise outside major hubs like Milan?
Yes. FTnet closed a $5M Seed in Napoli (July 2025), Oraigo raised $1M in Padova (July 2025), and Composite Research raised $1M in Pinerolo, Piemonte (October 2024). Seed activity in this dataset is distributed across at least six distinct Italian cities beyond Milano.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.